Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9C005
UPID:
DPY30_HUMAN
Alternative names:
Dpy-30-like protein
Alternative UPACC:
Q9C005; D6W578
Background:
The Protein dpy-30 homolog, also known as Dpy-30-like protein, plays a pivotal role in the methylation of histone H3 at 'Lys-4', a key epigenetic marker for transcriptional activation. This protein is integral to the MLL1/MLL complex, contributing to the trimethylation process essential for gene expression regulation. Beyond its epigenetic functions, it is involved in retinoic acid-induced differentiation in teratocarcinoma cells, marking its significance in neural lineage development.
Therapeutic significance:
Understanding the role of Protein dpy-30 homolog could open doors to potential therapeutic strategies, particularly in the realm of epigenetic disorders and differentiation therapies.